Laughter yoga's effects on IBS symptoms and mental health
Official title: The Effect of Laughter Yoga in Patients with Irritable Bowel Syndrome: a Randomized Controlled Trial
Run by Ataturk University · NCT06705153 · Data updated 2026-11-12
This study is testing if laughter yoga can help people with Irritable Bowel Syndrome feel better and improve their mental health.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 56 (estimated) |
| Sponsor | Ataturk University Academic / other |
| Locations | 1 site (Erzurum, Yakutiye) |
| Status | Recruiting |
| Started | December 4, 2024 |
| Main results expected | January 28, 2025 |
| Study ends | February 28, 2025 |
| Registry record updated | January 3, 2025 |
| Trial ID | NCT06705153 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 diagnosed with IBS who meet specific symptom severity and mental health criteria.
✕Probably not a fit
Patients with severe psychiatric conditions or those unable to participate in laughter yoga sessions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the impact of laughter yoga on patients with Irritable Bowel Syndrome (IBS) by measuring changes in symptom severity, depression, anxiety, stress, sleep quality, and overall quality of life. Participants will be randomly assigned to either an intervention group, which will engage in laughter yoga sessions twice a week for four weeks, or a control group that will not receive this intervention. Various validated scales will be used to assess the outcomes at baseline and after the intervention period, following CONSORT guidelines for randomized controlled trials.
Why it matters
Potential benefit: If successful, this approach could significantly improve the quality of life and mental health of patients suffering from IBS.
How similar studies have gone: While laughter yoga is a relatively novel approach for IBS, similar interventions focusing on mind-body techniques have shown promise in improving symptoms in other conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with IBS according to Rome IV criteria, * Scoring 75 and above on the IBS-SSS score, * DASS-42 scores of 10 and above for depression, 8 and above for anxiety, 15 and above for stress, * Over 18 years of age, * Bleeding hemorrhoids, all types of hernia, persistent cough, severe back pain, heart diseases, high blood pressure, urinary incontinence, major psychiatric diseases, pregnancy, cold/flu, no epilepsy, no surgery in the last three months, etc. * Patients with a smartphone/computer where it is possible to participate in a video call for laughter yoga, * Patients without communication problems and * Patients who agree to participate in the study will be included in the study. Exclusion Criteria: * who do not practice laughter yoga, * who do not attend regularly, * Patients whose treatment regimen has changed and * Patients who wish to leave the study will be excluded from the study.
Where it's running
-
Erzurum City Hospital
Erzurum, Yakutiye, Turkey (Türkiye) Recruiting
Study contacts
- Study coordinator: Ebru BALA
- Email: ebrubala23@gmail.com
- Phone: +905313854141
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Liver Fat and Scarring in People Suspected of Non-Celiac Wheat Sensitivity
This study looks to see if people with non-celiac wheat sensitivity have liver fat or fibrosis and how this relates to IBS/FD and celiac disease.
-
Repeated transcranial magnetic stimulation to treat diarrhea-predominant irritable bowel syndrome
This study will test whether repeated transcranial magnetic stimulation (rTMS) can reduce diarrhea, abdominal pain, and improve quality of life in adults with IBS-D.
-
Brenipatide (LY3537031) for IBS with constipation
This trial will test whether brenipatide (LY3537031), given by a small under-the-skin injection, helps adults with IBS-C have less belly pain and more normal bowel movements compared with a placebo.
-
Brenipatide (LY3537031) treatment for adults with IBS‑D
This will test whether brenipatide (LY3537031) given under the skin helps adults with IBS‑D reduce belly pain and improve stool consistency compared with placebo.
-
Camlipixant for IBS-D and IBS-M: a test in adults
This study tests camlipixant versus placebo in adults with IBS with diarrhea or mixed IBS to see if it helps reduce symptoms and is safe.
-
Defining Objective Markers of Dietary Compliance in IBS
This study tests whether a biomarker in stool or urine can reflect how much certain carbohydrates you eat, helping manage IBS.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.